Products

Results show that elderly patients undergoing non-instrumented fusion achieve statistically significantly higher fusion rates with i-FACTOR vs. allograft.

The JTA-004 Phase III study is approved in five of seven territories. These are the first patients treated after resumption of clinical activities.

InGeneron announces favorable study results using regenerative autologous adipose-derived cells that are prepared with the Transpose® RT System for treatment of partial-thickness rotator cuff tears.

BBS-Bioactive Bone Substitutes' patent application protecting ARTEBONE® bone graft substitute has been accepted in the U.S. 

Kuros Biosurgery was granted U.S. patents related to the MagnetOs product line and parathyroid hormones containing matrices for spinal fusion.

Regenerative medicine is an emerging market with solutions to not only heal but also grow tissue and bone. Renovos is addressing the issue of biological molecule diffusion through a synthetic nanoclay gel technology platform called Renovite.

Study results support the use of NuVasive's Attrax® Putty as a standalone bone graft substitute for autograft in instrumented thoracolumbar posterolateral lumbar fusion.

DiscGenics completed enrollment in its Phase I/II first-in-human U.S. clinical study of injectable disc cell therapy to treat degenerative disc disease.

Biocomposites commenced U.S. launch of STIMULAN® Rapid Cure 3cc synthetic calcium sulfate, designed specifically for smaller voids in the foot and ankle.

Bone Solutions announced successful implantation in over 1,000 cases with magnesium-based OsteoCrete® bone void filler.